Working to Eradicate Gynecologic Cancers

SIS8
Special Interest Session VIII: The First Department of Defense Ovarian Academy Abstract Session

Monday, March 30, 2015: 4:00 PM-5:15 PM
Continental Ballroom (Hilton Chicago)
Description: This course focuses on the latest science coming from the Department of Defense's Ovarian Academy. Abstracts will be presented by the scholars of the Ovarian Academy as a collective forum, promoting dialogue in the research and treatment of gynecologic cancers.
Faculty:  Anda Vlad, PhD, Magee-Womens Hospital of UPMC, Pittsburgh, PA and Panagiotis A, Konstantinopoulos, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA
Moderators:  Jeff Boyd, PhD, Fox Chase Cancer Center, Philadelphia, PA and Douglas A. Levine, MD, Memorial Sloan Kettering Cancer Center, New York, NY
4:00 PM
Introductory Remarks
J. Boyd1 and D. A. Levine2
1Fox Chase Cancer Center, Philadelphia, PA, 2Memorial Sloan Kettering Cancer Center, New York, NY
 
4:02 PM
Beyond Cancer Stem Cells: What Pathways are Activated in Persistent Ovarian Cancer?
C. N. Landen Jr.
University of Virginia School of Medicine, Charlottesville, VA
 
4:11 PM
Intraperitoneal anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a preclinical ovarian cancer model
A. Vlad1,2, J. Mony2, L. Zhang3, T. Ma4, T. Tirodkar5, S. Grabosch6, J. Brozick2, G. T. Tseng4 and R. P. Edwards1
1Magee-Womens Hospital of UPMC, Pittsburgh, PA, 2Magee Womens Research Institute, Pittsburgh, PA, 3Magee Womens Research Institute, 4University of Pittsburgh, Pittsburgh, PA, 5Mag, Pittsburgh, PA, 6Magee Womens Research Institute, Richmond Heights, PA
 
4:20 PM
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP-inhibitor Resistance
P. A. Konstantinopoulos1, R. Ceccaldi1, U. A. Matulonis2 and A. D'Andrea1
1Dana Farber Cancer Institute, Boston, MA, 2Dana-Farber Cancer Institute, Boston, MA
 
4:29 PM
Targeting Proteasome-Associated Deubiquitinating (DUBs) Enzyme for Ovarian Cancer Treatment
M. Bazzaro1, T. Pulver2, P. A. Argenta2 and R. Isaksson Vogel1
1University of Minnesota, MN 55455, MN, 2University of Minnesota, Minneapolis, MN
 
4:38 PM
Epidemiologic predictors of pre-treatment CA125 in women with ovarian cancer
K. Terry1, A. Babic2, B. Y. Karlan3, M. T. Goodman4, D. Lambrechts5, F. Heitz6, K. Matsuo7, I. McNeish8 and T. Pejovic9
1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Harvard School of Public Health, Boston, MA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of Hawaii Cancer Center, Honolulu, HI, 5Vesalius Research Center, Leuven, Belgium, 6Kliniken Essen-Mitte, Essen, Germany, 7Kyushu University, Nagoya, Japan, 8MRC/NCRI (Medical Research Council/National Cancer Research Institute), United Kingdom, 9Rogue Valley Medical Center, Medford, OR
 
4:47 PM
TP53 mutations in gynecologic cancers: translation from genomic knowledge into potential clinical applications
J. Chien, J. Madden, K. Minn, B. Herrman, R. Madan and A. Godwin
University of Kansas Medical Center, Kansas City, KS
 
4:56 PM
Wnt Signaling, Cellular Senescence and Ovarian Cancer Therapy
R. Zhang
The Wistar Institute, Philadelphia, PA
 
5:05 PM
Q & A
 
5:15 PM
A moderator of the session
J. Boyd
Fox Chase Cancer Center, Philadelphia, PA
 
5:15 PM
Moderator
D. A. Levine
Memorial Sloan Kettering Cancer Center, New York, NY
 
See more of: Special Interest Session
<< Previous Course | Next Course >>